Pneumocystis jirovecii pneumonia: A potential complication of sirolimus therapy.
Identifieur interne : 000260 ( Main/Exploration ); précédent : 000259; suivant : 000261Pneumocystis jirovecii pneumonia: A potential complication of sirolimus therapy.
Auteurs : Avinash K. Shetty [États-Unis]Source :
- Journal of paediatrics and child health [ 1440-1754 ] ; 2019.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Appréciation des risques (MeSH), Association de médicaments (MeSH), Femelle (MeSH), Humains (MeSH), Hémangioendothéliome (anatomopathologie), Hémangioendothéliome (immunologie), Hémangioendothéliome (traitement médicamenteux), Mâle (MeSH), Pneumocystis carinii (isolement et purification), Pneumonie à Pneumocystis (diagnostic), Pneumonie à Pneumocystis (traitement médicamenteux), Sarcome de Kaposi (anatomopathologie), Sarcome de Kaposi (immunologie), Sarcome de Kaposi (traitement médicamenteux), Sirolimus (administration et posologie), Sirolimus (effets indésirables), Sujet immunodéprimé (MeSH), Syndrome de Kasabach-Merritt (anatomopathologie), Syndrome de Kasabach-Merritt (immunologie), Syndrome de Kasabach-Merritt (traitement médicamenteux), Vincristine (administration et posologie), Études de cohortes (MeSH), Études de suivi (MeSH).
- MESH :
- administration et posologie : Sirolimus, Vincristine.
- anatomopathologie : Hémangioendothéliome, Sarcome de Kaposi, Syndrome de Kasabach-Merritt.
- diagnostic : Pneumonie à Pneumocystis.
- effets indésirables : Sirolimus.
- immunologie : Hémangioendothéliome, Sarcome de Kaposi, Syndrome de Kasabach-Merritt.
- isolement et purification : Pneumocystis carinii.
- traitement médicamenteux : Hémangioendothéliome, Pneumonie à Pneumocystis, Sarcome de Kaposi, Syndrome de Kasabach-Merritt.
- Adulte, Adulte d'âge moyen, Appréciation des risques, Association de médicaments, Femelle, Humains, Mâle, Sujet immunodéprimé, Études de cohortes, Études de suivi.
English descriptors
- KwdEn :
- Adult (MeSH), Cohort Studies (MeSH), Drug Therapy, Combination (MeSH), Female (MeSH), Follow-Up Studies (MeSH), Hemangioendothelioma (drug therapy), Hemangioendothelioma (immunology), Hemangioendothelioma (pathology), Humans (MeSH), Immunocompromised Host (MeSH), Kasabach-Merritt Syndrome (drug therapy), Kasabach-Merritt Syndrome (immunology), Kasabach-Merritt Syndrome (pathology), Male (MeSH), Middle Aged (MeSH), Pneumocystis carinii (isolation & purification), Pneumonia, Pneumocystis (diagnosis), Pneumonia, Pneumocystis (drug therapy), Risk Assessment (MeSH), Sarcoma, Kaposi (drug therapy), Sarcoma, Kaposi (immunology), Sarcoma, Kaposi (pathology), Sirolimus (administration & dosage), Sirolimus (adverse effects), Vincristine (administration & dosage).
- MESH :
- chemical , administration & dosage : Sirolimus, Vincristine.
- chemical , adverse effects : Sirolimus.
- diagnosis : Pneumonia, Pneumocystis.
- drug therapy : Hemangioendothelioma, Kasabach-Merritt Syndrome, Pneumonia, Pneumocystis, Sarcoma, Kaposi.
- immunology : Hemangioendothelioma, Kasabach-Merritt Syndrome, Sarcoma, Kaposi.
- isolation & purification : Pneumocystis carinii.
- pathology : Hemangioendothelioma, Kasabach-Merritt Syndrome, Sarcoma, Kaposi.
- Adult, Cohort Studies, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Immunocompromised Host, Male, Middle Aged, Risk Assessment.
DOI: 10.1111/jpc.14392
PubMed: 30957331
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pneumocystis jirovecii pneumonia: A potential complication of sirolimus therapy.</title>
<author><name sortKey="Shetty, Avinash K" sort="Shetty, Avinash K" uniqKey="Shetty A" first="Avinash K" last="Shetty">Avinash K. Shetty</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, North Carolina</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:30957331</idno>
<idno type="pmid">30957331</idno>
<idno type="doi">10.1111/jpc.14392</idno>
<idno type="wicri:Area/Main/Corpus">000305</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000305</idno>
<idno type="wicri:Area/Main/Curation">000305</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000305</idno>
<idno type="wicri:Area/Main/Exploration">000305</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Pneumocystis jirovecii pneumonia: A potential complication of sirolimus therapy.</title>
<author><name sortKey="Shetty, Avinash K" sort="Shetty, Avinash K" uniqKey="Shetty A" first="Avinash K" last="Shetty">Avinash K. Shetty</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, North Carolina</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of paediatrics and child health</title>
<idno type="eISSN">1440-1754</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Cohort Studies (MeSH)</term>
<term>Drug Therapy, Combination (MeSH)</term>
<term>Female (MeSH)</term>
<term>Follow-Up Studies (MeSH)</term>
<term>Hemangioendothelioma (drug therapy)</term>
<term>Hemangioendothelioma (immunology)</term>
<term>Hemangioendothelioma (pathology)</term>
<term>Humans (MeSH)</term>
<term>Immunocompromised Host (MeSH)</term>
<term>Kasabach-Merritt Syndrome (drug therapy)</term>
<term>Kasabach-Merritt Syndrome (immunology)</term>
<term>Kasabach-Merritt Syndrome (pathology)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Pneumocystis carinii (isolation & purification)</term>
<term>Pneumonia, Pneumocystis (diagnosis)</term>
<term>Pneumonia, Pneumocystis (drug therapy)</term>
<term>Risk Assessment (MeSH)</term>
<term>Sarcoma, Kaposi (drug therapy)</term>
<term>Sarcoma, Kaposi (immunology)</term>
<term>Sarcoma, Kaposi (pathology)</term>
<term>Sirolimus (administration & dosage)</term>
<term>Sirolimus (adverse effects)</term>
<term>Vincristine (administration & dosage)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Appréciation des risques (MeSH)</term>
<term>Association de médicaments (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hémangioendothéliome (anatomopathologie)</term>
<term>Hémangioendothéliome (immunologie)</term>
<term>Hémangioendothéliome (traitement médicamenteux)</term>
<term>Mâle (MeSH)</term>
<term>Pneumocystis carinii (isolement et purification)</term>
<term>Pneumonie à Pneumocystis (diagnostic)</term>
<term>Pneumonie à Pneumocystis (traitement médicamenteux)</term>
<term>Sarcome de Kaposi (anatomopathologie)</term>
<term>Sarcome de Kaposi (immunologie)</term>
<term>Sarcome de Kaposi (traitement médicamenteux)</term>
<term>Sirolimus (administration et posologie)</term>
<term>Sirolimus (effets indésirables)</term>
<term>Sujet immunodéprimé (MeSH)</term>
<term>Syndrome de Kasabach-Merritt (anatomopathologie)</term>
<term>Syndrome de Kasabach-Merritt (immunologie)</term>
<term>Syndrome de Kasabach-Merritt (traitement médicamenteux)</term>
<term>Vincristine (administration et posologie)</term>
<term>Études de cohortes (MeSH)</term>
<term>Études de suivi (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Sirolimus</term>
<term>Vincristine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Sirolimus</term>
<term>Vincristine</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Hémangioendothéliome</term>
<term>Sarcome de Kaposi</term>
<term>Syndrome de Kasabach-Merritt</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Pneumonia, Pneumocystis</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Pneumonie à Pneumocystis</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hemangioendothelioma</term>
<term>Kasabach-Merritt Syndrome</term>
<term>Pneumonia, Pneumocystis</term>
<term>Sarcoma, Kaposi</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Hémangioendothéliome</term>
<term>Sarcome de Kaposi</term>
<term>Syndrome de Kasabach-Merritt</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Hemangioendothelioma</term>
<term>Kasabach-Merritt Syndrome</term>
<term>Sarcoma, Kaposi</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Pneumocystis carinii</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Pneumocystis carinii</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Hemangioendothelioma</term>
<term>Kasabach-Merritt Syndrome</term>
<term>Sarcoma, Kaposi</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hémangioendothéliome</term>
<term>Pneumonie à Pneumocystis</term>
<term>Sarcome de Kaposi</term>
<term>Syndrome de Kasabach-Merritt</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Cohort Studies</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Immunocompromised Host</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Risk Assessment</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Appréciation des risques</term>
<term>Association de médicaments</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Sujet immunodéprimé</term>
<term>Études de cohortes</term>
<term>Études de suivi</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30957331</PMID>
<DateCompleted><Year>2020</Year>
<Month>10</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>10</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1440-1754</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>55</Volume>
<Issue>4</Issue>
<PubDate><Year>2019</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Journal of paediatrics and child health</Title>
<ISOAbbreviation>J Paediatr Child Health</ISOAbbreviation>
</Journal>
<ArticleTitle>Pneumocystis jirovecii pneumonia: A potential complication of sirolimus therapy.</ArticleTitle>
<Pagination><MedlinePgn>484</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/jpc.14392</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shetty</LastName>
<ForeName>Avinash K</ForeName>
<Initials>AK</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-4575-8996</Identifier>
<AffiliationInfo><Affiliation>Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Australia</Country>
<MedlineTA>J Paediatr Child Health</MedlineTA>
<NlmUniqueID>9005421</NlmUniqueID>
<ISSNLinking>1034-4810</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>5J49Q6B70F</RegistryNumber>
<NameOfSubstance UI="D014750">Vincristine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C537007">Kaposiform Hemangioendothelioma</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006390" MajorTopicYN="N">Hemangioendothelioma</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016867" MajorTopicYN="Y">Immunocompromised Host</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D059885" MajorTopicYN="N">Kasabach-Merritt Syndrome</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045363" MajorTopicYN="N">Pneumocystis carinii</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011020" MajorTopicYN="N">Pneumonia, Pneumocystis</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012514" MajorTopicYN="N">Sarcoma, Kaposi</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014750" MajorTopicYN="N">Vincristine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year>
<Month>01</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2019</Year>
<Month>01</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2019</Year>
<Month>01</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>10</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30957331</ArticleId>
<ArticleId IdType="doi">10.1111/jpc.14392</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Caroline du Nord</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Shetty, Avinash K" sort="Shetty, Avinash K" uniqKey="Shetty A" first="Avinash K" last="Shetty">Avinash K. Shetty</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000260 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000260 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Bois |area= RapamycinFungusV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:30957331 |texte= Pneumocystis jirovecii pneumonia: A potential complication of sirolimus therapy. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30957331" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a RapamycinFungusV1
This area was generated with Dilib version V0.6.38. |